SG11201505272QA - Age-related macular degeneration treatment - Google Patents
Age-related macular degeneration treatmentInfo
- Publication number
- SG11201505272QA SG11201505272QA SG11201505272QA SG11201505272QA SG11201505272QA SG 11201505272Q A SG11201505272Q A SG 11201505272QA SG 11201505272Q A SG11201505272Q A SG 11201505272QA SG 11201505272Q A SG11201505272Q A SG 11201505272QA SG 11201505272Q A SG11201505272Q A SG 11201505272QA
- Authority
- SG
- Singapore
- Prior art keywords
- age
- macular degeneration
- related macular
- degeneration treatment
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750086P | 2013-01-08 | 2013-01-08 | |
| PCT/AU2014/000007 WO2014107763A1 (en) | 2013-01-08 | 2014-01-08 | Age-related macular degeneration treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505272QA true SG11201505272QA (en) | 2015-08-28 |
Family
ID=51166430
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201705518SA SG10201705518SA (en) | 2013-01-08 | 2014-01-08 | Age-Related Macular Degeneration Treatment |
| SG11201505272QA SG11201505272QA (en) | 2013-01-08 | 2014-01-08 | Age-related macular degeneration treatment |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201705518SA SG10201705518SA (en) | 2013-01-08 | 2014-01-08 | Age-Related Macular Degeneration Treatment |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10000753B2 (en) |
| EP (1) | EP2943571A4 (en) |
| JP (1) | JP2016507514A (en) |
| KR (1) | KR20150103280A (en) |
| CN (1) | CN105143450A (en) |
| AU (1) | AU2014205036A1 (en) |
| CA (1) | CA2897342A1 (en) |
| HK (1) | HK1218656A1 (en) |
| IL (1) | IL239836A0 (en) |
| MX (1) | MX2015008697A (en) |
| RU (1) | RU2015133252A (en) |
| SG (2) | SG10201705518SA (en) |
| WO (1) | WO2014107763A1 (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
| SG11201604692UA (en) * | 2013-12-12 | 2016-07-28 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | Nmda receptor antagonists for treating gaucher disease |
| EP3218484A4 (en) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| RU2749882C2 (en) * | 2014-11-14 | 2021-06-18 | Вояджер Терапьютикс, Инк. | Modulating polynucleotides |
| EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
| EP3294280A1 (en) | 2015-05-11 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
| KR20180063881A (en) | 2015-07-16 | 2018-06-12 | 바이오카인 테라퓨틱스 리미티드 | Compositions and methods for the treatment of cancer |
| EP3405024B1 (en) | 2016-01-21 | 2022-12-28 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Parthenocarpic plants and methods of producing same |
| US20190046497A1 (en) | 2016-02-14 | 2019-02-14 | Yeda Research And Development Co., Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
| CN109073660B (en) * | 2016-02-29 | 2022-10-28 | 麦恩泰科特有限公司 | Predictive markers useful for the treatment of wet age-related macular degeneration |
| RU2758488C2 (en) | 2016-05-18 | 2021-10-28 | Вояджер Терапьютикс, Инк. | Modulating polynucleotides |
| JP7220080B2 (en) | 2016-05-18 | 2023-02-09 | ボイジャー セラピューティクス インコーポレイテッド | Compositions and methods for treating Huntington's disease |
| IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
| KR102495222B1 (en) * | 2016-12-14 | 2023-02-09 | 베니텍 아이피 홀딩스 아이엔씨. | Treatment of Ophthalmopharyngeal Dystrophy (OPMD) and Uses Thereof |
| TW201827596A (en) * | 2016-12-23 | 2018-08-01 | 日商協和醱酵麒麟有限公司 | Nucleic acid inhibiting expression of complement factor B |
| WO2018141025A1 (en) * | 2017-02-03 | 2018-08-09 | Benitec Biopharma Limited | Reagents for treatment of ocular diseases and conditions associated with neovascularisation and use thereof |
| WO2018204803A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Methods of treating psychiatric stress disorders |
| US11541072B2 (en) * | 2017-06-27 | 2023-01-03 | Massachusetts Eye And Ear Infirmary | AAV-CRISPR/Cas9 genome editing of VEGFR2 for treating ocular diseases |
| IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combination therapy for the treatment of cancer |
| BR112020005103A2 (en) * | 2017-09-15 | 2020-09-24 | Commonwealth Scientific And Industrial Research Organisation | rna molecule, chimeric ribonucleic acid (rna) molecule, isolated and / or exogenous polynucleotide, vector, host cell, polynucleotide, non-human organism, method, method for producing a non-human organism, extract of a host cell, composition, method to downwardly regulate the level and / or activity of a target RNA molecule in an organism, method to control a non-human organism, method to treat a disease in an individual, RNA molecule, use of an RNA molecule and kit |
| AU2018336128B2 (en) | 2017-09-19 | 2023-01-05 | Tropic Biosciences UK Limited | Modifying the specificity of plant non-coding RNA molecules for silencing gene expression |
| EP3704252A1 (en) | 2017-11-01 | 2020-09-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with improved properties |
| IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
| GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
| GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
| IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
| CA3153727A1 (en) * | 2019-09-10 | 2021-03-18 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Treatment methods for eye disorders |
| IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
| EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
| WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
| KR20230132472A (en) | 2020-12-18 | 2023-09-15 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Composition for use in the treatment of CHD2 haploid dysfunction and method for determining the same |
| IL304068A (en) | 2020-12-28 | 2023-08-01 | 1E Therapeutics Ltd | P21 mrna targeting dnazymes |
| IL304047A (en) | 2020-12-28 | 2023-08-01 | 1E Therapeutics Ltd | P21 mrna target areas for silencing |
| GB202103256D0 (en) | 2021-03-09 | 2021-04-21 | Tropic Biosciences Uk Ltd | Method for silencing genes |
| EP4337197A1 (en) | 2021-05-10 | 2024-03-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Pharmaceutical compositions for treating neurological conditions |
| EP4396346A1 (en) * | 2021-09-02 | 2024-07-10 | Silence Therapeutics GmbH | Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell |
| CA3234612A1 (en) | 2021-10-14 | 2023-04-20 | Weedout Ltd. | Methods of weed control |
| IL312399A (en) | 2021-10-29 | 2024-06-01 | Alnylam Pharmaceuticals Inc | Complement factor b (cfb) irna compositions and methods of use thereof |
| WO2024149907A2 (en) | 2023-01-13 | 2024-07-18 | Laverock Therapeutics Limited | Novel polynucleotides, cells and methods |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| US7309487B2 (en) | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
| EP2363483A3 (en) | 2004-03-05 | 2014-07-16 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of RNAi agents |
| CA2559161C (en) * | 2004-03-12 | 2013-06-11 | Alnylam Pharmaceuticals, Inc. | Irna agents targeting vegf |
| US8282921B2 (en) * | 2004-08-02 | 2012-10-09 | Paul Glidden | tRNA synthetase fragments |
| CN101180394B (en) | 2005-02-03 | 2013-01-09 | 贝尼泰克有限公司 | Rnai expression constructs |
| WO2006116756A1 (en) | 2005-04-28 | 2006-11-02 | Benitec, Limited. | Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns |
| AU2006315102A1 (en) | 2005-11-21 | 2007-05-24 | Johnson & Johnson Research Pty Limited | Multitargeting interfering RNAs having two active strands and methods for their design and use |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| HUE040417T2 (en) * | 2007-05-04 | 2019-03-28 | Marina Biotech Inc | Amino acid lipids and uses thereof |
| WO2008154482A2 (en) * | 2007-06-08 | 2008-12-18 | Sirnaomics, Inc. | Sirna compositions and methods of use in treatment of ocular diseases |
| US8283331B2 (en) * | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| US8470792B2 (en) | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
| WO2012015775A2 (en) | 2010-07-28 | 2012-02-02 | Dharmacon, Inc. | Sirna targeting vegfa and methods for treatment in vivo |
| US9220716B2 (en) | 2011-07-26 | 2015-12-29 | Children's Medical Center Corporation | Methods and compositions for the treatment of proliferative vascular disorders |
| AU2013225619A1 (en) | 2012-02-29 | 2014-10-16 | Benitec Biopharma Limited | Pain treatment |
-
2014
- 2014-01-08 CN CN201480010251.6A patent/CN105143450A/en active Pending
- 2014-01-08 AU AU2014205036A patent/AU2014205036A1/en not_active Abandoned
- 2014-01-08 WO PCT/AU2014/000007 patent/WO2014107763A1/en active Application Filing
- 2014-01-08 SG SG10201705518SA patent/SG10201705518SA/en unknown
- 2014-01-08 KR KR1020157021273A patent/KR20150103280A/en not_active Application Discontinuation
- 2014-01-08 CA CA2897342A patent/CA2897342A1/en not_active Abandoned
- 2014-01-08 RU RU2015133252A patent/RU2015133252A/en not_active Application Discontinuation
- 2014-01-08 JP JP2015551090A patent/JP2016507514A/en not_active Ceased
- 2014-01-08 US US14/759,401 patent/US10000753B2/en active Active
- 2014-01-08 MX MX2015008697A patent/MX2015008697A/en unknown
- 2014-01-08 SG SG11201505272QA patent/SG11201505272QA/en unknown
- 2014-01-08 EP EP14737958.0A patent/EP2943571A4/en not_active Withdrawn
-
2015
- 2015-07-08 IL IL239836A patent/IL239836A0/en unknown
-
2016
- 2016-06-08 HK HK16106608.3A patent/HK1218656A1/en unknown
-
2018
- 2018-04-27 US US15/964,584 patent/US20180320180A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1218656A1 (en) | 2017-03-03 |
| EP2943571A1 (en) | 2015-11-18 |
| CN105143450A (en) | 2015-12-09 |
| KR20150103280A (en) | 2015-09-09 |
| MX2015008697A (en) | 2016-08-04 |
| JP2016507514A (en) | 2016-03-10 |
| US10000753B2 (en) | 2018-06-19 |
| EP2943571A4 (en) | 2016-11-30 |
| WO2014107763A1 (en) | 2014-07-17 |
| CA2897342A1 (en) | 2014-07-17 |
| US20180320180A1 (en) | 2018-11-08 |
| US20160145611A1 (en) | 2016-05-26 |
| IL239836A0 (en) | 2015-08-31 |
| RU2015133252A (en) | 2017-02-10 |
| AU2014205036A1 (en) | 2015-07-30 |
| SG10201705518SA (en) | 2017-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218656A1 (en) | Age-related macular degeneration treatment | |
| IL266651A (en) | Implant | |
| HK1222994A1 (en) | Tobacco treatment | |
| HK1217490A1 (en) | Novel traps in the treatment of macular degeneration | |
| HK1217452A1 (en) | Prostamide-containing intraocular implant | |
| GB201308131D0 (en) | Ophthalmoscope | |
| EP2945639A4 (en) | Methods for treating cardiac conditions | |
| HK1215164A1 (en) | Treatment methods | |
| HK1214093A1 (en) | Tobacco treatment | |
| SG10201708547YA (en) | Compositions and methods for treating and preventing macular degeneration | |
| GB201304872D0 (en) | Treatment | |
| GB201308244D0 (en) | Soil treatment | |
| GB201616158D0 (en) | Age-related macular degeneration | |
| HK1216391A1 (en) | Combination treatment | |
| PL2826522T3 (en) | Pacemaker | |
| GB201307310D0 (en) | Treatment | |
| PT2777699T (en) | Diethylamine-2,5-dihydroxybenzenesulfonate for the treatment of age-related macular degeneration | |
| GB2514124B (en) | Turf Treatment | |
| GB201321115D0 (en) | Treatment | |
| GB201309238D0 (en) | Treatment | |
| IL230230A0 (en) | Implant | |
| GB201322764D0 (en) | Treating places | |
| GB201310756D0 (en) | Implant |